---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-203988"
form_type: "8-K"
ticker: "COAG"
cik: "0002114044"
company_name: "Hemab Therapeutics Holdings, Inc."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-15T00:07:04.192666+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Hemab Therapeutics completes IPO of 19.3M shares at $18.00, raising $346.7M

## Summary
- IPO of 19,262,500 shares at $18.00 per share, including full exercise of underwriter option for 2,512,500 shares.
- Gross proceeds of $346.7 million before underwriting discounts and estimated offering expenses.
- Common stock begins trading on Nasdaq Global Select Market under ticker 'COAG'.
- Restated certificate increases authorized common shares to 400M, establishes classified board with staggered three-year terms.
- Stockholder written consent and special meeting rights eliminated; exclusive forum provisions adopted.

## SEC filing metadata
- accession: 0001193125-26-203988
- form_type: 8-K
- ticker: COAG
- cik: 0002114044
- company_name: Hemab Therapeutics Holdings, Inc.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2114044/000119312526203988/0001193125-26-203988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2114044/000119312526203988/d149100d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-203988
- JSON: https://secwatch.observer/filing/0001193125-26-203988.json
- Plain text: https://secwatch.observer/filing/0001193125-26-203988.txt

## Source-grounded claims
- claim_id: 2d7179390aa334615ded7018b98ca04048214493
  claim: Hemab Therapeutics Holdings, Inc.: Filed a restated certificate of incorporation that increases authorized common stock, eliminates preferred stock references, authorizes undesignated preferred stock, establishes a classified board, modifies director removal and vacancy procedures, eliminates stockholder action by written consent and (effective 2026-05-04).
  evidence_excerpt: On May 4, 2026, Hemab Therapeutics Holdings, Inc. (the “Company”) filed a restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of common stock (the “IPO”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/2114044/000119312526203988/0001193125-26-203988-index.htm
- claim_id: 9b8538782e0f1a67c65c74cbdd3ee86a381e67e4
  claim: Hemab Therapeutics Holdings, Inc.: Amended and restated bylaws to eliminate stockholder action by written consent, establish procedures for stockholder proposals and director nominations, and conform to the restated certificate (effective 2026-05-04).
  evidence_excerpt: On May 4, 2026, in connection with the closing of the IPO, the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), which were previously approved by the Company’s board of directors and stockholders, became effective upon the closing of the IPO.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2114044/000119312526203988/0001193125-26-203988-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.